Amarin vs Zevra Therapeutics
AMRN and ZVRA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRN and ZVRA compare
Amarin is the larger company, worth 9.1 times as much as Zevra Therapeutics ($5.0B against $549M).
Zevra Therapeutics grew revenue faster over the last twelve months (119% versus −22.3% for Amarin).
Zevra Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.8% compared with −10.9% at Amarin.
Zevra Therapeutics scores higher on the StockData Score (15 against 10 for Amarin), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRN | ZVRA |
|---|---|---|
| Size and price | ||
| Market cap | $5.0B | $549M |
| Share price | $11.31 | $9.25 |
| Change, 1 year | −30.5% | 0.22% |
| Change, 5 years | −84.5% | 14.9% |
| Beta (5Y) | 0.73 | 1.18 |
| Employees | 80 | 61 |
| StockData Score | ||
| Total score | 10 | 15 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 3 | 3 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 9.9× |
| P/S | 28.4× | 4.0× (better) |
| P/B | 11.3× | 2.5× (better) |
| EV/EBITDA | – | 3.9× |
| P/FCF | – | 16.8× |
| FCF yield | – | 5.9% |
| Fair value | $7.00 | $23.75 |
| Margin of safety | −61.5% | 61.0% (better) |
| Growth | ||
| Revenue growth (TTM) | −22.3% | 119% (better) |
| Revenue growth, 5Y average | −19.0% | 51.6% (better) |
| Net income growth (TTM) | – | 2104% |
| Profitability | ||
| Gross margin | 40.9% | 95.5% (better) |
| Operating margin | −18.2% | 60.5% (better) |
| Net margin | −10.9% | 42.8% (better) |
| FCF margin | – | 24.0% |
| Return on equity | −4.2% | 34.8% (better) |
| Return on invested capital | −17.3% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Net debt / EBITDA | – | −2.64 |
| Interest coverage | – | 14.4× |
| Current ratio | 3.50 | 5.17 (better) |
| Altman Z-score | 12.95 (better) | 4.29 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 1.0% | 78.5% |
| Held by insiders | 7.0% | 1.2% |
| Insider net buying, 12 months | – | −$2.5M |
| Short interest, % of float | – | 11.2% |
Go deeper
- AMRN stock overview
- AMRN income statement
- AMRN valuation and score
- ZVRA stock overview
- ZVRA income statement
- ZVRA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.